Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 7, 2007, Pages 516-521

  McWilliams, Robert R ^a,e   Goetz, Matthew P ^a   Morlan, Bruce W ^a   Salim, Muhammad ^b   Rowland, Kendrith M ^c   Krook, James E ^d   Ames, Matthew M ^a   Erlichman, Charles ^a  

^a Mayo Clinic   (United States)

^b Allan Blair Cancer Centre   (Canada)

^c Carle Cancer Center Community Clinical Oncology Program   (United States)

^d Duluth Community Clinical Oncology Program   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Overall survival; Quality of life; Time to progression

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 34250668782     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.017     Document Type: Article

References (33)

1. Burris HA, Eckardt JR, Weiss G, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Ann Oncol 1996;7:491-496.
2. Rougier P, Bugat R, Douillard J, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-260.
3. Pitot H, Wender D, O'Connell M, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2910-2919.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
5. Goldberg RM, Sargent DJ, Fuchs CS, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study year. Proc Am Soc Clin Oncol 2002; 21:128a (Abstract #511).
6. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35:1343-1347.
7. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
8. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an Intergroup study. J Clin Oncol 2003; 22(12 suppl):252 (Abstract #1009).
9. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer 10.1200/JCO.2004.09.046. J Clin Oncol 2004; 22:23-30.
10. Guichard S, Arnould S, Hennebelle I, et al. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anti-Cancer Drugs 2001; 12:741-751.
11. Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21:3761-3769.
12. El-Khoueiry AB, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest 2006; 24:50-55.
13. Anton A, Massuti B, Rivera F, et al. Preliminary results of phase I-II study of the combination of oxaliplatin, irinotecan and 5-FU in patients (pts) with advanced solid (phase I) and CRC (phase II) tumours. J Clin Oncol 2003; 22(suppl 12):353 (Abstract #1417).
14. Calvo E, Cortes J, Rodriguez J, et al. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002; 2:104-110.
15. Reina JJ, Sanchez-Rovira P, Salvador J, et al. Biweekly administration of oxaliplatin (OX), irinotecan (CPT-11) and 5-fluorouracil as first line treatment of advanced or metastatic colorectal cancer (CRC). J Clin Oncol 2003; 22(suppl 12):320 (Abstract #1284).
16. Rubio G, Chacon M, Coppola F, et al. CPT-11/oxaliplatin (OXA) plus folinic acid (FA)/5-FU bolus (triple combination): an active and feasible combination in metastatic colorectal cancer (CRC) patients (pts). Proc Am Soc Clin Oncol 2002; 21:110b (Abstract #2254).
17. Seium Y, Stupp R, Ruhstaller T, et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 2005; 16:762-766.
18. Mini E, Nobili S, Mazzocchi V, et al. Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT-11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT-11- or OHP-based CHT. J Clin Oncol 2003; 22(suppl 12):374 (Abstract #1503).
19. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46:21-26.
20. Therasse P. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
21. Fleming TR. One-sample multiple testing procedure for phase 11 clinical trials. Biometrics 1982; 38:143-151.
22. Kaplan E, Meier P. Nonparametric estimation for incompletes observations. J Amer Stat Assoc 1958; 53:457-481.
23. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801-3807.
24. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
25. McLeod HL, Parodi L, Sargent DJ, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741. J Clin Oncol 2006; 24(18 suppl):3520 (Abstract #1515).
26. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226-1236.
27. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:678-682.
28. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-47.
29. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-1676.
30. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup trial. J Clin Oncol 2006; 24:3347-3353.
31. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
32. Falcone A Andreuccetti M, Orlandini C, et al. Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): subgroup and multivariate analysis. Presented at: Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Absract #287.
33. Goetz MP, Reid JM, Safgren SL, et al. UGT1A1*28 genotype determines the maximum tolerated dose (MTD) and pharmacokinetics (PK) of irinotecan based chemotherapy: a phase I dose-escalation trial. Presented at: Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract #235.